Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2015–2018

EpiPredict · Epigenetic regulation of endocrine therapy resistance in breast cancer: A systems medicine approach to predict treatment outcome

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2015-01-01 → 2018-12-31
EU contribution
€2,797,697
Participants
15
Scheme
MSCA-ITN-ETN

Lines connect the coordinator with its partners.

Results in brief

Epigenetic regulation of endocrine therapy resistance in breast cancer: A systems medicine approach to predict treatment outcome

EpiPredict’s mission was to train 12 early-stage researchers (ESRs) to fully exploit epigenetics of complex diseases. EpiPredict focused on endocrine therapy-induced resistance in Estrogen Receptor positive (ER+) breast cancer. Given frequent treatment failure, resistance prevention and reversal is an urgent clinical problem. We provided intersectorial training employing a timely systems medicine approach combining next-generation epigenetic, gene/protein profiling with innovative gene-specific epigenetic interference and computational modelling. EpiPedict's outstanding expertises and facilities enabled to identify key epigenetic changes underlying endocrine-therapy-induced resistance of impact as diagnostic/prognostic biomarkers to predict, monitor and improve endocrine treatment outcome. Strong involvement of the private sector ensured exploitation of achievements and exposure to an entrepreneurial mind-set. The ESRs gained urgently needed new approaches to address complex diseases taking personalized patient aspects into consideration, being equipped to succeed in their careers driving European translational science.

Data: CORDIS, © European Union

Project objective

The mission of EpiPredict is to train a multidisciplinary cohort of young researchers in a new approach to fully exploit the epigenetics of complex diseases. The 12 early-stage researchers (ESRs) will focus on a narrowly defined case, Tamoxifen-induced resistance in Estrogen Receptor positive (ER+) breast cancer, considering five resistance interacting pathways. Given the frequent Tamoxifen treatment failure, resistance prevention and reversal is an urgent clinical problem that is central in EpiPredict. The EpiPredict intersectorial training programme employs a timely systems medicine approach combining next-generation systematic epigenetic, gene/protein profiling with innovative gene-specific epigenetic interference technologies for iterative computational modelling. Together the ESRs will identify key epigenetic changes underlying Tamoxifen induced resistance. This will provide an important step towards diagnostic markers/tools to predict treatment outcome and response monitoring setting the scene for breast cancer personalized medicine. The fellows will be trained by experts from 6 academic and 2 non-academic beneficiaries and 7 partner organizations (1 academic, 6 non-academic including industrial/socio-public parties) and 5 visiting scientists, from fields ranging from epigenetics to both computation and medicine. Strong involvement of the private sector ensures exploitation of EpiPredict achievements and exposure of the ESRs to an entrepreneurial mindset. The cohort of supradisciplinary researchers represents a new generation of research leaders equipped to address complex diseases whilst taking personalized patient aspects into consideration. They will be equipped to compete successfully and succeed in their personal careers. EpiPredict will boost academia and pharma/biotech environments, providing extra impulses to drive European translational science, systems medicine, pharmaceutical industry, and Medical ICT offering ample job opportunities.

Original text from CORDIS.

Participants

  • UNIVERSITEIT VAN AMSTERDAM · AmsterdamCoordinatorNetherlands
  • ACADEMISCH ZIEKENHUIS GRONINGEN · GroningenNetherlands
  • AHT Management Kft · BudapestHungary
  • Biotecture · AmsterdamNetherlands
  • CLINICAGENO LIMITED · Coulsdon SurreyUnited Kingdom
  • DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG · HeidelbergGermany
  • EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH · ZuerichSwitzerland
  • Epiontis GmbH · BerlinGermany
  • FH JOANNEUM GESELLSCHAFT MBH · GrazAustria
  • HUN-REN SZEGEDI BIOLOGIAI KUTATOKOZPONT · SzegedHungary
  • IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE · LondonUnited Kingdom
  • Rathenau Instituut · DEN HAAGNetherlands
  • STIFTELSEN FRAUNHOFER-CHALMERS CENTRUM FOR INDUSTRIMATEMATIK · GOETEBORGSweden
  • Synvolux Therapeutics BV · LeidenNetherlands
  • UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA · MilanoItaly

Links

Data: CORDIS, © European Union